Gilder Gagnon Howe & Co. LLC Has $86 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Gilder Gagnon Howe & Co. LLC decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 365,463 shares of the biopharmaceutical company's stock after selling 18,530 shares during the period. Gilder Gagnon Howe & Co. LLC owned about 0.28% of Alnylam Pharmaceuticals worth $85,997,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Two Sigma Securities LLC lifted its holdings in Alnylam Pharmaceuticals by 272.3% during the 4th quarter. Two Sigma Securities LLC now owns 1,117 shares of the biopharmaceutical company's stock valued at $263,000 after purchasing an additional 817 shares during the last quarter. Kovitz Investment Group Partners LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 8.3% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 2,633 shares of the biopharmaceutical company's stock worth $620,000 after buying an additional 202 shares during the period. Integrated Wealth Concepts LLC grew its stake in Alnylam Pharmaceuticals by 7.5% in the 4th quarter. Integrated Wealth Concepts LLC now owns 2,512 shares of the biopharmaceutical company's stock valued at $591,000 after buying an additional 176 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. raised its holdings in Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 22,154 shares of the biopharmaceutical company's stock valued at $5,213,000 after acquiring an additional 413 shares during the period. Finally, T. Rowe Price Investment Management Inc. lifted its position in Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after acquiring an additional 1,245,195 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 1.3 %

NASDAQ ALNY traded down $3.39 on Thursday, reaching $259.85. The company had a trading volume of 628,050 shares, compared to its average volume of 880,778. The firm has a market cap of $33.80 billion, a price-to-earnings ratio of -119.21 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $143.96 and a fifty-two week high of $304.39. The business has a 50 day moving average of $247.81 and a two-hundred day moving average of $255.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.16) earnings per share. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

ALNY has been the topic of several research reports. StockNews.com downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research report on Friday, March 21st. Chardan Capital reaffirmed a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Stifel Nicolaus boosted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $315.58.

Insider Activity

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares of the company's stock, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Pushkal Garg sold 1,561 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the completion of the transaction, the chief marketing officer now directly owns 13,537 shares in the company, valued at approximately $3,454,236.29. This trade represents a 10.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,392 shares of company stock valued at $1,875,627. 1.50% of the stock is currently owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.